Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 287

1.

Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

Orr AL, Rutaganira FU, de Roulet D, Huang EJ, Hertz NT, Shokat KM, Nakamura K.

Neurochem Int. 2017 Apr 20. pii: S0197-0186(17)30037-2. doi: 10.1016/j.neuint.2017.04.006. [Epub ahead of print]

PMID:
28434973
2.

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA.

Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.

PMID:
28292440
3.

INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.

Reed DE, Shokat KM.

Mol Cancer Res. 2017 Feb 14. doi: 10.1158/1541-7786.MCR-16-0183. [Epub ahead of print]

PMID:
28196852
4.

An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.

Urisman A, Levin RS, Gordan JD, Webber JT, Hernandez H, Ishihama Y, Shokat KM, Burlingame AL.

Mol Cell Proteomics. 2017 Feb;16(2):265-277. doi: 10.1074/mcp.M116.058172. Epub 2016 Dec 11.

PMID:
27940637
5.

Endosomal Phosphatidylinositol 3-Kinase Is Essential for Canonical GPCR Signaling.

Uchida Y, Rutaganira FU, Jullié D, Shokat KM, von Zastrow M.

Mol Pharmacol. 2017 Jan;91(1):65-73. Epub 2016 Nov 7.

PMID:
27821547
6.

Discovery of new substrates of the elongation factor-2 kinase suggests a broader role in the cellular nutrient response.

Lazarus MB, Levin RS, Shokat KM.

Cell Signal. 2017 Jan;29:78-83. doi: 10.1016/j.cellsig.2016.10.006. Epub 2016 Oct 17.

PMID:
27760376
7.

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Ostrem JM, Shokat KM.

Nat Rev Drug Discov. 2016 Nov;15(11):771-785. doi: 10.1038/nrd.2016.139. Epub 2016 Jul 29. Review.

PMID:
27469033
8.

Overcoming resistance to HER2 inhibitors through state-specific kinase binding.

Novotny CJ, Pollari S, Park JH, Lemmon MA, Shen W, Shokat KM.

Nat Chem Biol. 2016 Nov;12(11):923-930. doi: 10.1038/nchembio.2171. Epub 2016 Sep 5.

9.

Innate immunity kinase TAK1 phosphorylates Rab1 on a hotspot for posttranslational modifications by host and pathogen.

Levin RS, Hertz NT, Burlingame AL, Shokat KM, Mukherjee S.

Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):E4776-83. doi: 10.1073/pnas.1608355113. Epub 2016 Aug 1.

10.

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A.

Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30.

PMID:
27364904
11.

Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.

Jo A, Choi TG, Jo YH, Jyothi KR, Nguyen MN, Kim JH, Lim S, Shahid M, Akter S, Lee S, Lee KH, Kim W, Cho H, Lee J, Shokat KM, Yoon KS, Kang I, Ha J, Kim SS.

Antioxid Redox Signal. 2017 Jan 10;26(2):70-83. doi: 10.1089/ars.2015.6457. Epub 2016 Aug 5.

PMID:
27357096
12.

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM.

Nature. 2016 Jun 9;534(7606):272-6. doi: 10.1038/nature17963. Epub 2016 May 18.

13.

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N.

Cancer Discov. 2016 Jul;6(7):727-39. doi: 10.1158/2159-8290.CD-15-1442. Epub 2016 May 26.

PMID:
27231123
14.

Multistep Compositional Remodeling of Supported Lipid Membranes by Interfacially Active Phosphatidylinositol Kinases.

Tabaei SR, Guo F, Rutaganira FU, Vafaei S, Choong I, Shokat KM, Glenn JS, Cho NJ.

Anal Chem. 2016 May 17;88(10):5042-5. doi: 10.1021/acs.analchem.6b01293. Epub 2016 Apr 28.

15.

N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.

Cancer Cell. 2016 Apr 11;29(4):536-47. doi: 10.1016/j.ccell.2016.03.001. Epub 2016 Mar 31.

16.

Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ.

Rutaganira FU, Fowler ML, McPhail JA, Gelman MA, Nguyen K, Xiong A, Dornan GL, Tavshanjian B, Glenn JS, Shokat KM, Burke JE.

J Med Chem. 2016 Mar 10;59(5):1830-9. doi: 10.1021/acs.jmedchem.5b01311. Epub 2016 Feb 26.

17.

Using hydrogen deuterium exchange mass spectrometry to engineer optimized constructs for crystallization of protein complexes: Case study of PI4KIIIβ with Rab11.

Fowler ML, McPhail JA, Jenkins ML, Masson GR, Rutaganira FU, Shokat KM, Williams RL, Burke JE.

Protein Sci. 2016 Apr;25(4):826-39. doi: 10.1002/pro.2879. Epub 2016 Feb 1.

18.

P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates.

Sansó M, Levin RS, Lipp JJ, Wang VY, Greifenberg AK, Quezada EM, Ali A, Ghosh A, Larochelle S, Rana TM, Geyer M, Tong L, Shokat KM, Fisher RP.

Genes Dev. 2016 Jan 1;30(1):117-31. doi: 10.1101/gad.269589.115.

19.

Analog sensitive chemical inhibition of the DEAD-box protein DDX3.

Floor SN, Barkovich KJ, Condon KJ, Shokat KM, Doudna JA.

Protein Sci. 2016 Mar;25(3):638-49. doi: 10.1002/pro.2857. Epub 2015 Dec 26.

20.

Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.

Kuhlenschmidt TB, Rutaganira FU, Long S, Tang K, Shokat KM, Kuhlenschmidt MS, Sibley LD.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):570-9. doi: 10.1128/AAC.01915-15.

Supplemental Content

Loading ...
Support Center